Please login to the form below
Rituxam
This page shows the latest Rituxam news and features for those working in and with pharma, biotech and healthcare.
Cancer drugs help Roche beat expectations in first quarter
Sales of Avastin and Herceptin show no sign of slowing down
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
- ‘Common Rulebook’ Brexit plans include medicines – but face backlash
- MaxCyte gets green light for solid tumour cell therapy
- Novartis rejects claims it misled Senate over Cohen links
- May’s Brexit plan cautiously welcomed by biopharma sector
- Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan
PMHub
Ashley Communications
Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...
Latest intelligence
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
- The rise of vertical integration in the US payer landscape
- Is it a solution to addressing the challenges of the value-based marketplace?...
- Creativity has lost its worth
- Creativity has lost its worth, and sadly it is undermining effectiveness...
Quick links
Infographics
